Next Science Ltd
ASX:NXS
Intrinsic Value
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. [ Read More ]
The intrinsic value of one NXS stock under the Base Case scenario is 1.254 AUD. Compared to the current market price of 0.315 AUD, Next Science Ltd is Undervalued by 75%.
Valuation Backtest
Next Science Ltd
Run backtest to discover the historical profit from buying and selling NXS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Next Science Ltd
Current Assets | 14m |
Cash & Short-Term Investments | 9.3m |
Receivables | 3.6m |
Other Current Assets | 1.1m |
Non-Current Assets | 3.9m |
PP&E | 1.5m |
Intangibles | 2.4m |
Other Non-Current Assets | 36.7k |
Current Liabilities | 3.8m |
Accounts Payable | 3.2m |
Accrued Liabilities | 79.7k |
Other Current Liabilities | 549.7k |
Non-Current Liabilities | 1.2m |
Long-Term Debt | 687.2k |
Other Non-Current Liabilities | 555.6k |
Earnings Waterfall
Next Science Ltd
Revenue
|
22.2m
USD
|
Cost of Revenue
|
-5.9m
USD
|
Gross Profit
|
16.2m
USD
|
Operating Expenses
|
-32.2m
USD
|
Operating Income
|
-15.9m
USD
|
Other Expenses
|
-343.6k
USD
|
Net Income
|
-16.3m
USD
|
Free Cash Flow Analysis
Next Science Ltd
NXS Profitability Score
Profitability Due Diligence
Next Science Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Next Science Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
NXS Solvency Score
Solvency Due Diligence
Next Science Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Next Science Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NXS Price Targets Summary
Next Science Ltd
According to Wall Street analysts, the average 1-year price target for NXS is 0.377 AUD with a low forecast of 0.343 AUD and a high forecast of 0.42 AUD.
Shareholder Return
NXS Price
Next Science Ltd
Average Annual Return | -16.95% |
Standard Deviation of Annual Returns | 29.96% |
Max Drawdown | -96% |
Market Capitalization | 91.9m AUD |
Shares Outstanding | 291 695 008 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
Contact
IPO
Employees
Officers
The intrinsic value of one NXS stock under the Base Case scenario is 1.254 AUD.
Compared to the current market price of 0.315 AUD, Next Science Ltd is Undervalued by 75%.